Shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the nine research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $63.00.
TGTX has been the topic of a number of analyst reports. Wall Street Zen raised TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 14th. B. Riley Financial raised their target price on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Weiss Ratings lowered shares of TG Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday. Zacks Research raised shares of TG Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th.
Check Out Our Latest Report on TG Therapeutics
TG Therapeutics Trading Down 2.4%
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.36 by ($0.01). TG Therapeutics had a return on equity of 18.82% and a net margin of 11.81%. The firm had revenue of $259.94 million for the quarter, compared to analysts’ expectations of $245.47 million. During the same period last year, the firm earned $2.43 EPS. TG Therapeutics’s revenue was up 60.8% compared to the same quarter last year. Equities analysts forecast that TG Therapeutics will post 1.19 EPS for the current year.
Insider Buying and Selling
In other news, Director Laurence Charney sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the sale, the director directly owned 168,640 shares of the company’s stock, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 8.87% of the company’s stock.
Institutional Investors Weigh In On TG Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Morse Asset Management Inc acquired a new position in TG Therapeutics during the third quarter worth about $29,000. Farther Finance Advisors LLC grew its position in TG Therapeutics by 45.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 993 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 312 shares in the last quarter. Bogart Wealth LLC purchased a new position in shares of TG Therapeutics during the third quarter valued at $56,000. Jacobi Capital Management LLC acquired a new position in shares of TG Therapeutics in the 3rd quarter valued at about $57,000. Finally, EverSource Wealth Advisors LLC lifted its position in TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 365 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.
TG Therapeutics Company Profile
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.
Recommended Stories
- Five stocks we like better than TG Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
